Fragment screening platforms are estimated at 39.0% by product in 2026, with nuclear magnetic resonance screening at 31.0% and oncology at 37.0%. Adoption depends on reliable weak-binding detection as protein quality and orthogonal confirmation constrain wider commercial use.
Fragment Based Drug Discovery Market Analysis By End UserFragment Based Drug Discovery Market Analysis By ProductFragment Based Drug Discovery Market Analysis By TechnologyFragment Based Drug Discovery Market Analysis By WorkflowFragment Based Drug Discovery Market Opportunity Matrix Growth Vs ValueFragment Based Drug Discovery Market Breakdown By Product, Technology, And Region